Ms. Dier joined Ultragenyx on October 12, 2020 and is responsible for leading the corporate finance, strategy, investor relations, corporate communications and information technology functions.
She joined Ultragenyx from Portola Pharmaceuticals (acquired by Alexion), where she served as Chief Financial Officer for 14 years and, most recently, also as Chief Business Officer. Over the course of her time at Portola she oversaw a wide range of functions including global supply chain. Prior to Portola, she served as Vice President of Investor Relations at Chiron Corporation until its acquisition by Novartis. Earlier in her career, she worked as an investment banker at Prudential Securities covering bio pharma, and prior to that was in the audit department of KPMG Peat Marwick. Ms. Dier serves on the Board of Directors of ORIC Pharmaceuticals, Prelude Therapeutics, and Synthakine, Inc.
She holds a B.S. in biology from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles.
Ms. Dier has been recognized twice as one of the most influential women in Bay Area business by the San Francisco Business Times (2013, 2019), and was a finalist for its Bay Area CFO of the Year Award (2013).